Finding what you are not looking for: Strategies for developing novel treatments in psychiatry

NeuroRx

Volumn 3, Issue 1, 2006, Pages 3-9

  Stahl, Stephen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEUROSCIENCE EDUCATION INSTITUTE   (United States)

Author keywords

Efficacy; Herapeutic target; Indication; New claims; Psychiatry; Psychopharmacology

Indexed keywords

ADDERAL XR; ALPRAZOLAM; AMFEBUTAMONE; AMPHETAMINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; DEPAKOTE ER; DEXAMPHETAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; INDIPLON MR; LAMOTRIGINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; OXYBATE SODIUM; PAROXETINE; PAXIL CR; PREGABALIN; PROZAC WEEKLY; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; XANAX XR; ZIPRASIDONE; ZOLPIDEM TARTRATE;

AGRANULOCYTOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE MARKER; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; HUMAN; PRESCRIPTION; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; REVIEW; TREATMENT OUTCOME;

EID: 33244468570     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2005.12.002     Document Type: Article

References (14)

1. Stahl SM. Needs and opportunities for innovation in psychopharmacology. J Royal Soc Med 80:413-417, 1987.
2. Stahl SM. Does evidence from clinical trials in psychopharmacology apply in clinical practice? J Clin Psychiatry 62:6-7, 2001.
3. Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work- from receptors to reality. NeuroRx 3:10-21, 2006.
4. Stahl SM. Essential psychopharmacology. 2nd ed. New York: Cambridge University Press, 2000.
5. Stahl SM. Essential psychopharmacology: the prescriber's guide. New York: Cambridge University Press, 2005.
6. Physician's desk reference, 2005.
7. Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx 3:117-130, 2006.
8. Apud JA. The pharmocogenomics of the dorsolateral prefrontal cortex: a new tool for the development of "target-oriented" cognitive enhancing drugs. NeuroRx 3:106-116, 2006.
9. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 3:57-68, 2006.
10. Carlson PJ, Singh JB, Zarate CA Jr, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 3:22-41, 2006.
11. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3:69-81, 2006.
12. Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry 64: 355-356, 2002.
13. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 63:56-57, 2002.
14. Holzheimer PE III, Nemeroff CB. Advances in the treatment of depression. NeuroRx 3:42-56, 2006.